Stock Analiz

Addex Therapeutics Ltd. ADXN

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$4.06Market cap $7M
Open the interactive analysis →

Addex Therapeutics Ltd. (ADXN) is a healthcare company listed in the US with a market value of about $7M. In the twelve months to June 30, 2026 it had revenue of $35743 and net income of -$8M, a net margin of -22923.5%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -123%.

About Addex Therapeutics

Addex Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $512323 in 2017 to $35743 in 2025, a decline of about 28.3% a year. It was profitable in 1 of the last 9 years in our data. Its share count fell by 47% over three years (buybacks).

Score: 0.6 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Share count down over 3 years (buybacks)

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S69.8
P/B3.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-41.1%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-733.8%
ROIC (5-yr avg.)-122.8%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 9 years

Fiscal yearTTM202520242023202220212020201920182017
Revenue$35743$35743—$2M$2M$3M$4M$3M$7M$512323
Net income-$8M-$8M$8M-$13M-$23M-$17M-$15M-$15M-$2M-$3M
Free cash flow-$3M-$3M-$6M-$10M-$18M-$16M-$14M-$10M$2M-$2M
EPS (diluted)$-7.56$-4.48$2.29$-3.70$-6.61$-4.94$-4.29$-4.49$-0.49$-0.99
Net margin-22923.5%-22448.4%—-654.5%-1462.6%-486.9%-331.5%-521.6%-24.5%-656.2%
ROIC——-28.5%-195.8%-214.6%-91.6%-83.8%-57.2%-3.6%-190.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Addex Therapeutics pay a dividend?

Not currently.

Is Addex Therapeutics a good stock to buy?

We do not give buy or sell advice. Addex Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.